Nyxoah SA NYXH shares rallied 13.2% in the last trading session to close at $8.81. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 43.8% loss over the past four weeks.Nyxoah SA scored a strong price increase on optimism surrounding the recent receipt of FDA’s Investigational Device Exemption (IDE) approval to initiate ACCCESS clinical trial. The trial is intended to assess the effectiveness of the Genio system to treat adult patients having moderate-to-severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate. Previously, the Genio gained FDA’s Breakthrough Device Designation to treat CCC patients.This company is expected to post quarterly loss of $0.32 per share in its upcoming report, which represents a year-over-year change of +15.8%. Revenues are expected to be $1.04 million, up 396.7% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Nyxoah SA, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NYXH going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Nyxoah SA is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Hims & Hers Health, Inc. HIMS, finished the last trading session 3.9% lower at $5.38. HIMS has returned 45.5% over the past month.Hims & Hers Health, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.10. Compared to the company's year-ago EPS, this represents a change of -25%. Hims & Hers Health, Inc. currently boasts a Zacks Rank of #3 (Hold). Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nyxoah SA (NYXH): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research